Henry Meds Compounded Oral Semaglutide (Dissolvable Tablets / Drops) review: is it worth it?

What is Henry Meds, and how does the oral semaglutide program work?

Henry Meds (operated by Adonis Health Inc.) is a direct-to-consumer telehealth company that launched in 2022 and built its business around making GLP-1 weight-loss medications cheaper by routing patients to compounding pharmacies rather than retail brand-name drugs. It is not a pharmacy or a manufacturer; it is a subscription service that bundles three things: an online medical consultation, ongoing provider access, and home-delivered medication.

The flow is typical of the category. You complete an online intake questionnaire covering weight, height, BMI, medical history, and current medications. A US-licensed clinician contracted through the platform reviews your information — sometimes asynchronously, sometimes via a HIPAA-compliant video visit — and, if you qualify, writes a prescription. That prescription is sent to a US-licensed compounding pharmacy (Henry Meds does not publicly name its pharmacy partners) which prepares and ships your medication monthly. There is no in-person exam and, in most cases, no required bloodwork.

For oral semaglutide specifically, Henry offers two delivery formats that are very different from each other and from anything sold in a regular pharmacy:

• A daily dissolving tablet (marketed as a mint-flavored "rapid dissolve" or oral troche), and
• Sublingual drops taken under the tongue.

This is a crucial distinction. The only oral semaglutide products that have been studied in human trials are *swallowed* tablets engineered for gastric absorption. Henry's dissolving tablets and sublingual drops are designed to absorb through the mouth's mucous membranes instead — a delivery route that has essentially no published, peer-reviewed efficacy data for semaglutide. Henry typically dispenses these oral/sublingual formats at roughly 1 mg per day, on the rationale that bypassing the gut requires less drug. Whether that 1 mg actually reaches the bloodstream in a therapeutic, consistent amount has not been established outside compounding-industry marketing materials.

How does semaglutide work — and why is the oral version so tricky?

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying, increases feelings of fullness, dampens appetite signaling in the brain, and enhances glucose-dependent insulin release. For most people the practical result is less hunger, earlier satiety, and lower calorie intake (NIH).

The molecule is a peptide, and peptides are notoriously hard to deliver by mouth — stomach acid and digestive enzymes destroy them, and large molecules cross the gut wall poorly. The brand-name oral semaglutide that *does* work (Rybelsus, and the newly approved oral Wegovy) only achieves this through a specialized co-formulation: each tablet is paired with an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which transiently raises local pH and helps semaglutide cross the stomach lining (FDA Rybelsus label). Even with SNAC, absolute oral bioavailability is only about 1% (FDA), which is why these products carry rigid dosing rules: take the tablet on an empty stomach after an overnight fast, with no more than about 4 ounces (120 mL) of plain water, swallowed whole, and eat or drink nothing for at least 30 minutes afterward. Food, extra water, or other beverages can sharply reduce absorption.

This pharmacology is the heart of the problem with compounded oral semaglutide. A dissolving troche or sublingual drop is not the SNAC-based gastric-absorption system that the trials validated. There is no published evidence establishing what dose of a sublingual or oral-dissolving compounded product reliably reaches the bloodstream, so the entire efficacy case rests on extrapolation, not data.

How well does oral semaglutide actually work in trials?

The trial evidence for oral semaglutide is genuinely strong — but it belongs to the *brand-name, FDA-regulated* product, not to Henry's compound.

The original PIONEER program supported the 2019 FDA approval of Rybelsus (oral semaglutide 7 mg and 14 mg) for type 2 diabetes glycemic control. In diabetes, those doses produced meaningful HbA1c reductions and modest weight loss — on the order of a few kilograms — because Rybelsus was developed primarily as a glucose-lowering drug, not a weight-loss drug (AJMC; FDA).

The obesity data came later and used much higher doses. In the OASIS 1 trial (a randomized, double-blind, placebo-controlled phase 3 study published in *The Lancet* in 2023), adults with overweight or obesity but without diabetes lost an estimated mean of 15.1% of body weight at 68 weeks on oral semaglutide 50 mg, versus 2.4% on placebo — a treatment difference of about 12.7 percentage points. In that trial, 69% of participants on the active drug reached at least 10% weight loss and 34% reached at least 20%, compared with 12% and 3% on placebo (Lancet 2023). Gastrointestinal side effects were common, reported in roughly 80% of the active-treatment group.

Those results led to the OASIS 4 trial of once-daily oral semaglutide 25 mg, on which the FDA based its December 2025 approval of the oral Wegovy pill — the first oral GLP-1 approved for chronic weight management (FDA; Novo Nordisk). OASIS 4 reported about 16.6% mean weight loss with treatment adherence.

The pattern is clear: meaningful weight loss from oral semaglutide required 25–50 mg per day of a SNAC-formulated, swallowed tablet manufactured under FDA oversight. Henry's compounded oral and sublingual products are dosed around 1 mg per day through a different, untested delivery route. There is no published trial showing that a 1 mg compounded sublingual or dissolving dose produces anything resembling OASIS-level results — or any clinically meaningful weight loss at all.

Is compounded oral semaglutide even legal right now?

This is the part most reviews skip, and it is decisive.

Compounding pharmacies are normally prohibited from mass-producing copies of an FDA-approved, patent-protected drug. A narrow exception applies when the FDA lists the brand drug as being in shortage — which is exactly what allowed telehealth companies like Henry to sell cheap compounded semaglutide in the first place.

On February 21, 2025, the FDA declared the semaglutide shortage resolved (FDA). That triggered hard wind-down deadlines: the FDA said it did not intend to take enforcement action against smaller state-licensed 503A pharmacies until about April 22, 2025, and larger 503B outsourcing facilities had until about May 22, 2025 (FDA; Alston & Bird). Compounders challenged the determination in court, but the shortage carve-out that justified routine semaglutide compounding is, for practical purposes, gone.

Limited exceptions survive — a 503A pharmacy can still compound a drug for an individual patient with a documented medical need that the approved product can't meet, such as a verified excipient allergy or a strength not commercially available. But routine compounding that amounts to a copy of an approved product is no longer protected. And in April 2026, the FDA proposed removing semaglutide from the 503B bulk-substances list entirely, which would further close off large-scale compounding (FDA; Pharmacy Times).

The bottom line on legality: any compounded semaglutide sold today sits in a legal gray-to-red zone, not the protected shortage exemption that originally justified the entire low-cost model.

How safe is it, and what are the side effects?

Two separate safety layers matter here: the risks of the drug class, and the risks specific to *compounding*.

Compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality (FDA). That is not boilerplate. In a July 2024 alert, the FDA documented concrete harms with compounded *injectable* semaglutide, including dosing errors and overdoses — in some reports patients or providers measured out 5 to 20 times the intended dose from multiple-dose vials — with adverse events such as severe nausea, vomiting, abdominal pain, dehydration, fainting, and pancreatitis (FDA, 2024 alert). Oral and sublingual compounds avoid that specific draw-up error, but raise a different concern. The agency has also flagged compounded products made with unapproved salt forms (semaglutide sodium, semaglutide acetate) that differ chemically from the semaglutide base in approved drugs. For an oral or sublingual compound, there is an added uncertainty: without validated bioavailability testing, you cannot know whether you're getting an underdose (no benefit), an erratic dose, or a product that degrades in storage.

GLP-1 class risks apply regardless of source. Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (FDA Wegovy/Rybelsus labels). Other recognized risks include acute pancreatitis, gallbladder disease, acute kidney injury (often from dehydration due to vomiting/diarrhea), diabetic retinopathy complications in some patients, and reports of ileus. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are dose-related, which is one reason brand programs titrate slowly (FDA). It is also notable that in OASIS 4, serious adverse events were actually *less* frequent on oral semaglutide than placebo (3.9% vs 8.8%), underscoring that the validated brand product has a well-characterized safety profile — something a compound cannot claim.

How do you take it, and what does dosing look like?

Henry's oral and sublingual products are taken daily, typically starting around 1 mg/day, with the platform's clinicians managing titration through follow-up. For the *sublingual* format, the medication is held under the tongue to absorb through oral tissue. For *dissolving tablets*, it dissolves in the mouth. Crucially, these instructions diverge from the strict empty-stomach, plain-water, swallow-whole protocol that makes brand-name oral semaglutide work — because the products are attempting a different absorption route entirely. The honest framing is that there is no validated, evidence-based dosing schedule for compounded sublingual semaglutide; the regimen is the pharmacy's, not a tested one.

What does it cost, and is it good value?

Reported pricing for Henry's oral semaglutide has ranged widely depending on dose tier and prepayment — figures cited across reviews span roughly $99 to $249 per month, with higher doses costing more and the lowest per-month rates generally requiring longer prepaid commitments. Pricing for the oral formats is often not shown until you start the intake quiz. Henry promotes that its medication cost is bundled into the monthly fee with no separate consultation charge, and that purchases may qualify for HSA/FSA reimbursement.

On value, the assessment has to be skeptical. The price looks attractive next to brand-name GLP-1s, but you are not buying the same thing. The newly approved brand oral Wegovy pill launched in early January 2026 at about $149/month cash-pay for its starter doses (1.5 mg and 4 mg), with the higher maintenance doses (9 mg and 25 mg) priced around $299/month through NovoCare (Novo Nordisk) — meaning the validated, FDA-approved product is at least in the same broad price range as Henry's compound, but with actual trial data, FDA quality oversight, and a known absorbed dose. When a compounded ~1 mg sublingual product of unproven bioavailability costs in the same range as a clinically validated semaglutide tablet, "cheaper" stops being the right lens. Cheap is not good value if the product may not deliver a therapeutic dose.

How does it compare to the alternatives?

• Brand-name oral Wegovy / Rybelsus: FDA-approved, SNAC-formulated, swallowed tablets with real efficacy and safety data. Oral Wegovy (25 mg) is now the evidence-backed choice for oral GLP-1 weight loss; Rybelsus (7/14 mg) is approved for diabetes with modest weight effects.
• Brand injectable GLP-1s (Wegovy, Zepbound): The most potent, best-studied options. Wegovy 2.4 mg produced about 14.9% mean weight loss in STEP 1 (NEJM 2021); tirzepatide 15 mg reached roughly 20.9% mean weight loss in the total-population analysis of SURMOUNT-1 (NEJM 2022). Manufacturer cash-pay programs (NovoCare, LillyDirect) have made these more accessible without the compounding question mark.
• Other compounding telehealth platforms (Hims, Ro, etc.): Largely the same legal and safety exposure as Henry post-shortage. The differentiators are pricing transparency and how much live clinician contact you get — not whether the underlying compounded product is validated.
• In-person obesity-medicine clinic with insurance: If your plan covers a GLP-1, this is almost always cheaper and safer, with real monitoring and the genuine FDA-approved drug.

The bottom line

Henry Meds is a legitimate, convenient telehealth front end, and its providers and process function as advertised. But its compounded oral semaglutide is a fundamentally weaker product than its marketing implies. The impressive 15–17% weight-loss numbers belong to *brand-name* oral semaglutide at 25–50 mg in SNAC-formulated, swallowed tablets studied in the OASIS trials — not to a roughly 1 mg compounded sublingual or dissolving product delivered through an untested absorption route, with no efficacy data of its own, no FDA quality oversight, and a legal basis that largely collapsed when the semaglutide shortage was declared resolved in 2025. With an FDA-approved oral Wegovy pill now available — starting around $149/month cash-pay for lower doses and roughly $299/month at the 25 mg maintenance dose — the strongest argument for the compounded version, affordability, is far weaker than it was during the shortage. Anyone considering Henry's oral semaglutide should weigh it against the approved alternatives and discuss the choice with an independent clinician who knows their full medical history; for most people, a product with real trial data and a known absorbed dose is the more defensible decision.